Pseudotyping Retrovirus Like Particles Vaccine Candidates with Hepatitis C Virus Envelope Protein E2 Requires the Cellular Expression of CD81

Overview

Journal AMB Express

Date 2019 Feb 8

PMID 30729353

Citations 3

Authors

Hugo R Soares

Rute Castro

Helio A Tomas

Manuel J T Carrondo

Paula M Alves

Ana S Coroadinha

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infects 3% of world population being responsible for nearly half a million deaths annually urging the need for a prophylactic vaccine. Retrovirus like particles are commonly used scaffolds for antigens presentation being the core of diverse vaccine candidates. The immunogenicity of host proteins naturally incorporated in retrovirus was hypothesized to impact the performance of retrovirus based vaccines. In this work, the capacity of engineered retrovirus like particles devoided of host protein CD81 to display HCV envelope antigens was compared to non-engineered particles. A persistent inability of CD81 negative VLPs to incorporate HCV E2 protein as a result from the inefficient transport of HCV E2 to the plasma membrane, was observed. This work enabled the identification of a CD81-mediated transport of HCV E2 while stressing the importance of host proteins for the development of recombinant vaccines.

Citing Articles

Viruses as tools in gene therapy, vaccine development, and cancer treatment.

Umair M, Akusa F, Kashif H, Seerat-E-Fatima , Butt F, Azhar M Arch Virol. 2022; 167(6):1387-1404.

PMID: 35462594 PMC: 9035288. DOI: 10.1007/s00705-022-05432-8.

The ATPase ATP6V1A facilitates rabies virus replication by promoting virion uncoating and interacting with the viral matrix protein.

Liu X, Li F, Zhang J, Wang L, Wang J, Wen Z J Biol Chem. 2020; 296:100096.

PMID: 33208464 PMC: 7949080. DOI: 10.1074/jbc.RA120.014190.

Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.

Kalemera M, Capella-Pujol J, Chumbe A, Underwood A, Bull R, Schinkel J J Gen Virol. 2020; 102(1).

PMID: 33147126 PMC: 8116788. DOI: 10.1099/jgv.0.001512.

References

Bartosch B, Dubuisson J, Cosset F . Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003; 197(5):633-42. PMC: 2193821. DOI: 10.1084/jem.20021756. View

Op de Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z . Characterization of functional hepatitis C virus envelope glycoproteins. J Virol. 2004; 78(6):2994-3002. PMC: 353750. DOI: 10.1128/jvi.78.6.2994-3002.2004. View

Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M . Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol. 2004; 34(10):2834-42. DOI: 10.1002/eji.200424887. View

Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset F . DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine. 2006; 24(14):2643-55. DOI: 10.1016/j.vaccine.2005.11.034. View

Segura M, Garnier A, Di Falco M, Whissell G, Meneses-Acosta A, Arcand N . Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J Virol. 2007; 82(3):1107-17. PMC: 2224463. DOI: 10.1128/JVI.01909-07. View

Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset F . Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med. 2009; 11(4):313-25. DOI: 10.1002/jgm.1307. View

Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel M, Despres P . DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine. 2009; 27(42):5772-80. DOI: 10.1016/j.vaccine.2009.07.059. View

Rodrigues A, Guerreiro M, Santiago V, Dalba C, Klatzmann D, Alves P . Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: tailoring vector composition. Biotechnol Bioeng. 2011; 108(11):2623-33. DOI: 10.1002/bit.23231. View

Garrone P, Fluckiger A, Mangeot P, Gauthier E, Dupeyrot-Lacas P, Mancip J . A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011; 3(94):94ra71. DOI: 10.1126/scitranslmed.3002330. View

10.

Roughan J, Reardon K, Cogburn K, Quendler H, Pockros P, Law M . Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin Vaccine Immunol. 2012; 19(7):1027-37. PMC: 3393369. DOI: 10.1128/CVI.00194-12. View

11.

Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O . Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine. 2012; 31(11):1540-7. DOI: 10.1016/j.vaccine.2012.05.025. View

12.

Bellier B, Klatzmann D . Virus-like particle-based vaccines against hepatitis C virus infection. Expert Rev Vaccines. 2013; 12(2):143-54. DOI: 10.1586/erv.13.10. View

13.

Kirchmeier M, Fluckiger A, Soare C, Bozic J, Ontsouka B, Ahmed T . Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol. 2013; 21(2):174-80. PMC: 3910943. DOI: 10.1128/CVI.00662-13. View

14.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

15.

Baumert T, Fauvelle C, Chen D, Lauer G . A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014; 61(1 Suppl):S34-44. DOI: 10.1016/j.jhep.2014.09.009. View

16.

Urbanowicz R, McClure C, Brown R, Tsoleridis T, Persson M, Krey T . A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. J Virol. 2015; 90(7):3288-301. PMC: 4794667. DOI: 10.1128/JVI.02700-15. View

17.

Soares H, Castro R, Tomas H, Rodrigues A, Gomes-Alves P, Bellier B . Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity. Vaccine. 2016; 34(13):1634-1641. DOI: 10.1016/j.vaccine.2015.12.015. View

18.

Lussignol M, Kopp M, Molloy K, Vizcay-Barrena G, Fleck R, Dorner M . Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis. Proc Natl Acad Sci U S A. 2016; 113(9):2484-9. PMC: 4780614. DOI: 10.1073/pnas.1518934113. View

19.

Pitoiset F, Vazquez T, Levacher B, Nehar-Belaid D, Derian N, Vigneron J . Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation. J Virol. 2017; 91(21). PMC: 5640832. DOI: 10.1128/JVI.01230-17. View

20.

Gogesch P, Schulke S, Scheurer S, Muhlebach M, Waibler Z . Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b APC and antigen-specific T cell responses in vitro. Mol Immunol. 2018; 101:19-28. DOI: 10.1016/j.molimm.2018.05.017. View